Τόμος 28 (2010) – Τεύχος 2 – Άρθρο 2 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 28 (2010) – Issue 2 – Article 2 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Από | | Άρθρο - Article, Παναγιώτα Κυριάκου,Panagiota Kyriakou, Πλήρες Κείμενο στα Ελληνικά - Full Text in Greek, Χαραλαμπία Κυριάκου,Charalabia Kyriakou
Τίτλος – Title

Επιδημιολογία, Ταξινόμηση, Παθογένεια Ιδιοπαθούς Διατατικής Καρδιομυοπάθειας

Idiopathic Dilated Cardiomyopathy: Epidemiology, Classification and Pathogenesis
Συγγραφέας – Author

Παναγιώτα Κυριάκου1, Χαραλαμπία Κυριάκου2

1Β΄ Παθολογική Κλινική, Ιπποκράτειο Νοσοκομείο, Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάς
2Consultant Haematologist, North West London NHS Trust, Royal Free and UCL Medical School, London, UK

 

Panagiota Kyriakou1, Charalabia Kyriakou2

12nd Dept. of Cardioliology, Ippokrateion Clinic, Aristotle University, Thessaloniki, Hellas
2Consultant Haematologist, North West London NHS Trust, Royal Free and UCL Medical School, London, UK
Παραπομπή – Citation

Κυριάκου,Π., Κυριάκου,Χ. : Επιδημιολογία, Ταξινόμηση, Παθογένεια Ιδιοπαθούς Διατατικής Καρδιομυοπάθειας, Επιθεώρηση Κλιν. Φαρμακολ. Φαρμακοκινητ. 28: 96-111 (2010)

Kyriakou,P., Kyriakou,Ch. : Idiopathic Dilated Cardiomyopathy: Epidemiology, Classification and Pathogenesis, Epitheorese Klin. Farmakol. Farmakokinet. 28: 96-111 (2010)
Ημερομηνία Δημοσιευσης – Publication Date
1 Δεκεμβρίου 2010 – 2010-12-01
Γλώσσα Πλήρους Κειμένου –
Full Text Language

Ελληνικά – Greek
Παραγγελία – Αγορά –
Order – Buy
Ηλεκτρονική Μορφή: pdf (15 €) –
Digital Type: pdf (15 €)
pharmakonpress[at]pharmakonpress[.]gr
Λέξεις κλειδιά – Keywords
–
–
Λοιποί Όροι – Other Terms

‘Αρθρο

Article
Περίληψη – Summary

–

Cardiomyopathies are primary pathological disorders of the myocardium caused by inheritant transmitted functional and anatomical disturbances. Idiopathic or Sporadic Dilated Cardiomyopathy is the commonest form, and represents one of the basic backgrounds of heart failure. The idiopathic form of dilated cardiomyopathy is sub-classified into two subgroups, the familial form that is inheritant and the sporadic purely idiopathic cardiomyopathy of unknown cause. In 30-50% of the cases, the illness is of genetically determined disorders, concerning the mutations of genes responsible for the cytoskeleton proteins, adherens junction proteins, nuclear envelope and nuclear lamina proteins, sarcomeric proteins and mitochondrial DNA. Clinically it is characterised by unexplained ventricular dilatation with impaired systolic function of LV or RV or both ventricles. The diagnosis should be made by excluding all secondary causes of cardiac dilatation. In this paper we review the existing data regarding both the idiopathic and the familial forms of dilated cardiomyopathy. Other contributing factors such as myocarditis, viruses, autoimmune mechanisms, toxins such as alcohol and the isolated left ventricular non¬compaction cardiomyopathy are also discussed. The vast majority of all these disorders are directly or indirectly inherited forms of heart failure which is the final common clinical manifestation whatever the underlying cause is. The value of molecular diagnostics is restricted to investigation, guidance and consultation for the familial forms of the disease.
Αναφορές – References
 1. Kaski J.P., Elliott P.: The classification concept of the ESC Working Group on myocardial and pericardial diseases for dilated cardiomyopathy. Herz 32: 446-451 (2007)

2. Hess O.Μ., MacKenna W., Schultheiss H.-P., with coauthors Hullin R., Kyuhl O., Pauschinger M., Noutsias M., Sen-Chowdhry S.: Myocardial disease. In: The ESC text-book of Cardiovascular Medicine: Chapter 16, pp: 453, 463-473.

3. Joshua Wynne, Eugene Braunwald: Cardiomyopathies. In: Braunwald Cardiology. 7th Edition, Volume 2, Chapter 59, pp. 1162-1164, 2005 (Greek edition)

4. Schultheiss H.P., Noutsias M., Kuhl U., et al.: Cardio-myopathies. I: classification of cardiomyopathies-dilated cardiomyopathy. Internist (Berl) 46: 1245-1256 (2005) (AB¬STRACT)

5. Murphy R.T., Starling R.C.: The genetics of cardiomyopathy: Implications for clinical practice. Καρδιακή Ανεπάρκεια 2(1): 21-34 (2005)

6. Erhardt A., Mellenthin C., Perings C., et al.: HFE mutations in idiopathic dilated cardiomyopathy. Med. Klin. (Mu-nich) 101(Suppl 1):135-138 (2006)

7. Ashrafian H., Watkins H.: Reviews of translational medicine and genomics in cardiovascular disease: new disease taxonomy and therapeutic implications cardiomyopathies: therapeutics based on molecular phenotype. J. Am. Coll. Cardiol. 49: 1251-1264 (2007)

8. Baig M.K., Goldman J.H., Caforio A., al.: Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may present early disease. J. Am. Coll. Cardiol. 31: 195-201 (1998)

9. Mahon N.G., Madden B.P., Caforio A.L., et al.: Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 39: 455-462 (2002)

10. Mestroni L., Maisch B., McKenna W.J., et al.: Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur. Heart J. 20: 93-102 (1999)

11. Mestroni L., Rocco C., Gregori D., et al.: Familial dilated cardiomyopathy: evidence of genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J. Am. Coll. Cardiol. 34: 181-90 (1999)

12. SOLVD: Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N. Engl. J. Med. 325: 293-302 (1991)

13. Pasotti M., Klersy C., Pilotto A., et al.: Long-term outcome and risk stratification in dilated cardiolaminopathies. J. Am. Coll. Cardiol. 52: 1250-1260 (2008)

14. Vatta M., Stetson S.J., Perez-Verdia A., et al.: Molecular remodelling of dystrophin in patients with end stage cardiomyopathies and reversal in patients on assistance device therapy. Lancet 359: 936-941 (2002)

15. Jerosch-Herold M., Sheridan D.C., Kushner J.D., et al.: Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am. J. Physiol Heart Circ. Physiol. 295: H1234-H1242 (2008)

16. Remondino A., Kwon S.H., Communal C., et al.: Adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2–terminal kinase-dependent activation of the mitochondrial pathway. Circ. Res. 92: 136-138 (2003)

17. Leri A., Claudio P.P., Li Q., et al.: Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local reninangiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J. Clin. Invest. 101: 1326-1342 (1998)

18. Ing D.J., Zang J., Dzau V.J., et al.: Modulation of cytokine induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. Circ. Res. 84: 21-33 (1999)

19. Miura K., Matsumori A., Nasermoaddeli A., et al.: Prognosis and prognostic factors in patients with idiopathic dilated cardiomyopathy in Japan. Circ. J. 72: 343-348 (2008)

20. Haddad G.E., Saunders L.J., Crosby S.D., et al.: Human cardiac specific cDNA array for idiopathic dilated cardiomyopathy: sex-related differences. Physiol. Genomics 33: 267-277 (2008)

21. Arvanitis D.A., Sanoudou D., Kolokathis F., et al.: The Ser96Ala variant in histidine rich calcium-binding protein is associated with life-threatening ventricular arrhythmias in idiopathic dilated cardiomyopathy. Eur. Heart J. 29: 2514-2525 (2008)

22. Brooksbank R., Badenhorst D., Sliwa K., Norton G., Woodiwiss A.: The G-308A polymorphism of the TNF-alpha gene does not predict changes in cardiac function in response to medical therapy for idiopathic dilated cardiomyopathy. Cardiovasc. J. Afr. 19: 254-258 (2008)

23. Brembilla-Perrot B., Alla F., Suty-Selton C., et al.: Non¬ischemic dilated cardiomyopathy: results of noninvasive and invasive evaluation in 310 patients and clinical significance of bundle branch block. Pacing Clin. Electrophysiol. 31: 1383-1390 (2008)

24. Chen C.A., Hsiao C.H., Wang J.K., et al.: Implication of QRS prolongation and its relation to mechanical dyssynchrony in idiopathic dilated cardiomyopathy in childhood. Am. J. Cardiol. 103: 103-109 (2009)

25. Mason J.W.: Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc. Res. 60: 5-10.ESC (2003)

26. Zhang H., Li Y., McClean D.R., et al.: Detection of enterovirus capsid protein VP1 in myocardium from cases of myocarditis or dilated cardiomyopathy by immunohisto-chemistry: further evidence of enterovirus persistence in myocytes. Med. Microbiol. Immunol. (Berl) 193: 109-114 (2004)

27. Kuhl U., Pauschinger M., Schwimmbeck P.L., et al.: Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107: 2793-2798 (2003)

28. Andreoletti L., Bourlet T., Moukassa D., et al.: Enteroviruses can persist with or without active viral replication in cardiac tissue of patients with end-stage ischemic or dilated cardiomyopathy. J. Infect. Dis. 182: 1222-1227 (2000)

29. Caforio A.L., Iliceto S.: Genetically determined myocarditis: clinical presentation and immunological characteristics. Curr. Opin. Cardiol. 23: 219-226 (2008)

30. Portig I., Sandmoeller A., Kreilinger S., Maisch B.: HLA-DQB1* polymorphism and associations with dilated cardiomyopathy, inflammatory dilated cardiomyopathy and myocarditis. Autoimmunity 42: 33-40 (2009)

31. Bowles N.A., Ni J., Kearney D.L., et al.: Detection of viruses in myocardial tissues by polymerase chain reaction. Evidence of adenovirus as a common cause of myocarditis in children and adults. J. Am. Coll. Cardiol. 42: 466-472 (2003)

32. Kuhl U., Pauschinger M., Noutsias M., et al.: High prevalence of viral genomes and multiple viral infections in the myocardium of adults with idiopathic left ventricular dysfunction. Circulation 111: 887-893 (2005)

33. Angelow A., Schmidt M., Hoffmann W.: Towards risk factor assessment in inflammatory dilated cardiomyopathy: the SFB/TR 19 study. Eur. J. Cardiovasc. Prev. Rehabil. 14: 686-693 (2007)

34. Portig I., Kliebe F., Kliebe C., Ruppert V., Maisch B.: HSPA1B polymorphism in familial forms of inflammatory dilated cardiomyopathy. Int. J. Cardiol. (2008)

35. Schultheiss H.P., Kuhl U.: Overview on chronic viral cardiomyopathy/chronic myocarditis. Ernst. Schering Res. Found. Workshop 55: 3-18 (2006)

36. Kallwellis-Opara A., Dorner A., Poller W.C., et al.: Autoimmunological features in inflammatory cardiomyopathy. Clin. Res. Cardiol. 96: 469-480 (2007)

37. Caforio A.L., Mahon N.G., McKenna W.J.: Clinical implications of anticardiac immunity in dilated cardiomyopathy. Ernst. Schering Res. Found. Workshop 55: 169-193 (2006)

38. Portig I., Wilke A., Freyland M., et al.: Familial inflammatory dilated cardiomyopathy. Eur. J. Heart Fail. 8: 816-825 (2006)

39. Caforio A.L., Mahon N.J., Tona F., et al.: Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur. Heart Fail. 4: 411-417 (2002)

40. Wojnicz R., Nowlany-Kozielska E., Wojciechowska C., et al.: Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardio-myopathy: two-year follow-up results. Circulation 104: 39-45 (2001)

41. Mahon N.G., Zal B., Arno G., et al.: Absence of viral nucleic acids in early and late dilated cardiomyopathy. Heart 86: 687-692 (2001)

42. Haddad G.E., Saunders L., Carles M., et al.: Fingerprint profile of alcohol associated heart failure in human hearts. Alcohol Clin. Exp. Res. 32: 814-821 (2008)

43. Steffel J., Kobza R., Namdar M., et al.: Electrophysiological findings in patients with isolated left ventricular non-compaction. Europace 11: 1193-1200 (2009)

44. Rigopoulos A., Rizos I.K., Aggeli C., et al.: Isolated left ventricular noncompaction: an unclassified cardiomyopathy with severe prognosis in adults. Cardiology 98: 25-32 (2002)

45. Ichida F., Tsubata S., Bowles K.R., et al.: Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation 103: 1256-1263 (2001)

46. Vatta M., Mohapatra B., Jimenez S., et al.: Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non compaction. J. Am. Coll. Cardiol. 42: 2014-2027 (2003)

47. Kovacevic-Preradovic T., Jenni R., Oechslin E.N., et al.: Isolated left ventricular noncompaction as a cause for heart failure and heart transplantation: a single center experience. Cardiology 112: 158-164 (2009)

48. Κίτσιος Γ., Χατζηγεωργίου Γ., Τρυποσκιάδης Φ.: Γενετική των μιτοχονδριακών μυοκαρδιοπαθειών. Καρδιακή Ανεπάρκεια 2: 131-145 (2005)

49. Brega A., Narula J., Arbustini E.: Functional, structural and genetic mitochondrial abnormalities in myocardial diseases. J. Nucl. Cardiol. 8: 89-97 (2001)

50. Zhang D., Ezekiel U.R., Chang S.W., Zassenhaus H.P.: Gene expression profile in dilated cardiomyopathy caused by elevated frequencies of mitochondrial DNA mutations in the mouse heart. Cardiovasc. Pathol. 14: 61-69 (2005)

51. Smith P.M., Ross G.F., Taylor R.W., et al.: Strategies for treating disorders of the mitochondrial genome. Biochim. Biophys. Acta 1659: 232-239 (2004)

52. Di Mauro S., Hirano M., Schon E.A.: Mitochondrial encephalomyopathies: therapeutic approaches. Neurol. Sci. 21(5 Suppl): S901-908

53. Colombo M.G., Botto N., Vittorini S., Paradossi U., Andreassi M.G.: Clinical utility of genetic tests for inherited hypertrophic and dilated cardiomyopathies. Cardiovasc. Ultrasound 6: 62 (2008)

54. Τρυποσκιάδης Φ.Κ.: Οικογενής διατατική μυοκαρδιοπά-θεια. Καρδιακή ανεπάρκεια 1: 199-204 (2004)

55. Di Lenarda A., Pinamonti B., Mestroni L., et al.: The natural history of dilated cardiomyopathy: a review of the Heart Disease Registry of Triste. Ital. Heart 5(Suppl.): 253-266 (2004)

56. Michels V.V., Driscoll D.J., Miller F.A., et al.: Progression of familial and non-familial dilated cardiomyopathy: a long term follow-up. Heart 89: 757-761 (2003)

57. Cicoira M., Zanolla L., Latina L., et al.: Frequency, prognosis and predictors of improvement of left ventricular function in patients with classical clinical diagnosis of idiopathic dilated cardiomyopathy. Eur. J. Heart Fail. 3: 323-330 (2001)

58. Bahler R.C.: Assessment of prognosis in idiopathic dilated cardiomyopathy. Chest 121: 1016-1019 (2002)

 

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
• Chemical Abstracts

• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Articles published in this Journal are Indexed or Abstracted in:
• Chemical Abstracts
• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση
Articles Published in Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Συντακτικη Επιτροπή-Editorial Board

ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ – ANNUAL SUBSCRIPTION
Γλώσσα Πλήρους Κειμένου –
Full Text Language
Ελληνικά – Greek
Παραγγελία – Αγορά –
Order – Buy
pharmakonpress[at]pharmakonpress[.]gr
pharmakonpress[at]pharmakonpress[.]gr

 

Προσθέστε στους σελιδοδείκτες το μόνιμο σύνδεσμο.

Τα σχόλια είναι απενεργοποιημένα.